These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24108210)

  • 1. Inflammatory bowel diseases: from pathogenesis to laboratory testing.
    Basso D; Zambon CF; Plebani M
    Clin Chem Lab Med; 2014 Apr; 52(4):471-81. PubMed ID: 24108210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.
    Jaskowski TD; Litwin CM; Hill HR
    Clin Vaccine Immunol; 2006 Jun; 13(6):655-60. PubMed ID: 16760323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
    Sipponen T; Kolho KL
    Scand J Gastroenterol; 2015 Jan; 50(1):74-80. PubMed ID: 25523558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological antibodies in inflammatory bowel disease: a systematic review.
    Prideaux L; De Cruz P; Ng SC; Kamm MA
    Inflamm Bowel Dis; 2012 Jul; 18(7):1340-55. PubMed ID: 22069240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of fecal markers of inflammation in inflammatory bowel disease.
    Judd TA; Day AS; Lemberg DA; Turner D; Leach ST
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1493-9. PubMed ID: 21777275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fecal lactoferrin in identifying and management of inflammatory bowel disease].
    Pac-Kozuchowska E; Krawiec P; Mroczkowska-Juchkiewicz A
    Pol Merkur Lekarski; 2014 Jul; 37(217):61-4. PubMed ID: 25154203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
    Caccaro R; D'Incá R; Sturniolo GC
    Expert Rev Clin Immunol; 2010 Jul; 6(4):551-8. PubMed ID: 20594128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relevance of serologic studies in inflammatory bowel diseases].
    Papp M; Altorjay I; Lakatos PL
    Orv Hetil; 2007 May; 148(19):887-96. PubMed ID: 17478404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
    Mokrowiecka A; Gasiorowska A; Małecka-Panas E
    Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
    Stragier E; Van Assche G
    Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
    Sipponen T
    Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of fecal biomarkers in inflammatory bowel disease.
    Sutherland AD; Gearry RB; Frizelle FA
    Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases.
    Inoue K; Aomatsu T; Yoden A; Okuhira T; Kaji E; Tamai H
    J Gastroenterol Hepatol; 2014; 29(7):1406-12. PubMed ID: 24635100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
    Mendoza JL; Abreu MT
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour.
    Ferrante M; Henckaerts L; Joossens M; Pierik M; Joossens S; Dotan N; Norman GL; Altstock RT; Van Steen K; Rutgeerts P; Van Assche G; Vermeire S
    Gut; 2007 Oct; 56(10):1394-403. PubMed ID: 17456509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.